2-Apr-2026
TipRanks (Mon, 30-Mar 4:45 AM ET)
Market Chameleon (Fri, 20-Mar 6:17 AM ET)
Market Chameleon (Thu, 19-Mar 4:16 AM ET)
Business Wire (Thu, 19-Mar 6:10 AM ET)
Guardian Pharmacy Services Announces Launch of Underwritten Public Offering of Class A Common Stock
Business Wire (Wed, 18-Mar 4:20 PM ET)
Business Wire (Wed, 11-Mar 4:05 PM ET)
Business Wire (Tue, 10-Mar 4:30 PM ET)
Business Wire (Thu, 12-Feb 4:30 PM ET)
Business Wire (Mon, 9-Feb 4:30 PM ET)
Guardian Pharmacy Services Reiterates 2025 Guidance and Provides 2026 Outlook
Business Wire (Tue, 13-Jan 4:30 PM ET)
Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.
Guardian Pharmacy Services Class A trades on the NYSE stock market under the symbol GRDN.
As of April 2, 2026, GRDN stock price climbed to $37.99 with 542,662 million shares trading.
GRDN has a beta of 0.28, meaning it tends to be less sensitive to market movements. GRDN has a correlation of 0.01 to the broad based SPY ETF.
GRDN has a market cap of $2.44 billion. This is considered a Mid Cap stock.
Last quarter Guardian Pharmacy Services Class A reported $398 million in Revenue and $.37 earnings per share. This beat revenue expectation by $8 million and exceeded earnings estimates by $.11.
The top ETF exchange traded funds that GRDN belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
GRDN has outperformed the market in the last year with a price return of +80.8% while the SPY ETF gained +18.2%. GRDN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +26.3% and +12.0%, respectively, while the SPY returned -3.6% and -0.6%, respectively.
GRDN support price is $36.28 and resistance is $38.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRDN shares will trade within this expected range on the day.
